Study guide
3.3 Pulmonary Disease Progression
Certified Hospice and Palliative Nurse CHPN
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current Exam Facts 1.2 Eligibility, Fees, Windows, and Retakes 1.3 Scoring, Test-Day Rules, and Remote Proctoring 1.4 Recertification: HPAR and the Situational Judgment Exercise
2 Chapter 2: Assessment, Goals, and Care Planning
2.1 Goals of Care and Shared Decision Making 2.2 Interdisciplinary Care Planning and Ongoing Evaluation 2.3 Prognostic and Functional Assessment Tools 2.4 Levels of Care and Care-Setting Transitions
3 Chapter 3: Life-Limiting Disease Progression I
3.1 Cancer, Hematologic, and Paraneoplastic Complications 3.2 Heart Failure and Cardiac Disease Progression 3.3 Pulmonary Disease Progression 3.4 Neurologic Disease Progression
4 Chapter 4: Disease Progression II and Imminent Death
4.1 Dementia, Frailty, and Feeding Decisions 4.2 Renal, Hepatic, and Endocrine Trajectories 4.3 Indicators of Imminent Death
5 Chapter 5: Pain Assessment
5.1 Pain Types, Etiology, and Syndromes 5.2 Verbal and Nonverbal Pain Assessment and Scales 5.3 Factors That Influence the Pain Experience
6 Chapter 6: Pharmacologic Pain Management
6.1 Opioid and Non-Opioid Analgesics by Pain Type and Severity 6.2 Adjuvant Analgesics 6.3 Titration, Baseline Dosing, and Breakthrough Pain 6.4 Equianalgesic Conversion and Route Changes
7 Chapter 7: Nonpharmacologic Pain and Opioid Safety
7.1 Nonpharmacologic Pain Interventions 7.2 Complementary and Integrative Pain Therapies 7.3 Opioid Adverse Effects, Neurotoxicity, and Rotation
8 Chapter 8: Neurological, Cardiovascular, and Respiratory Symptoms
8.1 Neurological Symptoms 8.2 Delirium and Terminal Restlessness 8.3 Cardiovascular Symptoms 8.4 Respiratory Symptoms: Dyspnea, Cough, and Secretions
9 Chapter 9: Gastrointestinal, Genitourinary, and Musculoskeletal Symptoms
9.1 Gastrointestinal Symptoms 9.2 Genitourinary Symptoms 9.3 Musculoskeletal Symptoms
10 Chapter 10: Skin, Metabolic, Hematologic, and Psychospiritual Symptoms
10.1 Skin and Mucous Membrane Symptoms 10.2 Nutritional and Metabolic Symptoms 10.3 Immune and Hematologic Symptoms 10.4 Psychosocial, Emotional, and Spiritual Symptom Burden
11 Chapter 11: Advance Care Planning, Benefits, and Safety
11.1 Advance Care Planning and Life-Sustaining Therapies 11.2 Hospice and Palliative Benefits under Medicare, Medicaid, and Private Insurance 11.3 Patient Safety: Environmental, Physical, and Socioemotional
12 Chapter 12: Communication, Culture, and Psychosocial Support
12.1 Communication Techniques, Barriers, and Family Meetings 12.2 Cultural Humility and Spiritual Needs 12.3 Psychosocial Needs and IDG Participation
13 Chapter 13: Caregiver Education and Medication Management
13.1 Medication Management and Controlled Substances 13.2 Caregiver and Family Self-Care 13.3 Teaching End-Stage Disease, Pain, and Symptom Plans 13.4 Caregiver Skills, DME, Supplies, and Services
14 Chapter 14: Grief, Death, and End-of-Life Ethics
14.1 Grief, Loss, and Bereavement 14.2 Support at the Time of Death and Post-Mortem Care 14.3 Ethical Issues Related to End of Life
15 Chapter 15: Medicare Hospice Compliance and National Standards
15.1 Medicare Hospice Benefit and Conditions of Participation 15.2 Hospice Eligibility, Admission, and Recertification 15.3 National Hospice and Palliative Care Standards 15.4 National Consensus Project Clinical Practice Guidelines
16 Chapter 16: Legal, Professional Practice, Quality, and Policy
16.1 Legal Regulations: CMS, HIPAA, and OSHA 16.2 Professional Boundaries and Ethics 16.3 QAPI, Self-Care, and Precepting 16.4 Policy, Delivery, and Reimbursement Trends
3.3 Pulmonary Disease Progression
Key Takeaways Explain This Topic AI
In chronic hypercapnic COPD, a usual oxygen saturation target is about 88–92%; do not over-oxygenate as a reflex to drive the saturation to 100%.
Interstitial lung disease, especially idiopathic pulmonary fibrosis, often declines faster than COPD, with high oxygen need and little reversible airway disease.
A dyspnea crisis is panic and air hunger in a still-perfused patient; active dying looks like apnea, Cheyne–Stokes breathing, and mottling. Morphine or hydromorphone are first-line dyspnea drugs; detailed titration is taught later.
Noninvasive ventilation can palliate COPD or ALS-overlap respiratory failure or become a mask burden that only prolongs dying; secretion burden needs positioning and planned suction limits, not endless airway assault.
Last updated: August 2026
Lung trajectories the CHPN exam actually writes
Pulmonary disease on Domain 1.C is not a pulmonary-function-test trivia contest. The 150-item HPCC CHPN exam wants you to recognize chronic obstructive pulmonary disease (COPD) as a long curve with crashes, interstitial lung disease (ILD) / idiopathic pulmonary fibrosis (IPF) as a faster slide, pulmonary hypertension as right-heart failure with infusion complexity, and lung cancer as an overlap that can add hemoptysis, obstruction, and the solid-tumor drop from Section 3.1. Dyspnea treatment with opioids is introduced here because it is how dying lungs are comforted; milligram-by-milligram titration belongs in a later symptom chapter.
COPD: FEV1, BODE, and the 88–92% oxygen rule
Forced expiratory volume in one second (FEV1) stages obstruction, but hospice eligibility is a function-and-crisis story, not a single percent predicted. A patient with FEV1 under 30% predicted is often in very severe obstruction, yet a higher FEV1 with cachexia, right-heart strain, and back-to-back exacerbations can be just as late. The BODE index (body-mass index, obstruction, dyspnea, exercise capacity) is a conceptual prognostic bundle: lower BMI, worse FEV1, worse dyspnea grade, and shorter six-minute walk all point to higher mortality. You are not asked to compute BODE by hand on every stem, but you should recognize that dyspnea and exercise capacity can outweigh a “not that low” FEV1.
CO2 retainers live with chronic hypercapnia. The operational CHPN rule is: in chronic hypercapnia, target oxygen saturation about 88–92% . Do not over-oxygenate as a reflex. Driving saturation to 100% with high-flow oxygen can worsen hypercapnia (V/Q mismatch and the Haldane effect—not the old “never give oxygen or they will stop breathing” myth). Treat hypoxemia; do not treat the pulse-oximeter’s desire for a perfect number.
COPD exacerbations are the hospitalizations that mark decline: more frequent, less complete recovery, more home oxygen, more noninvasive ventilation (NIV) in the emergency department. Between crashes, the patient may still sit in a chair. That recovered-looking interval is why families delay hospice. Name the stacked exacerbations as the trajectory.
ILD/IPF, pulmonary hypertension, and lung-cancer overlap
IPF and many fibrotic ILDs do not reverse with bronchodilators. The curve is often shorter than COPD: rising oxygen liters, dry cough, clubbing, and an acute exacerbation that is frequently a terminal event rather than a recoverable COPD flare. High-flow oxygen at home is common. Prognosis after an ILD exacerbation is poor enough that a hospice referral during that hospitalization is not “giving up too soon.”
Pulmonary hypertension presents with exertional syncope, edema, and right-heart failure. Prostacyclin infusions and other pulmonary vasodilators create the same coverage problem as cardiac inotropes: selected programs continue them for comfort, many hospices cannot. Coordinate; do not yank a drip without a plan for rebound pulmonary hypertensive crisis if the goal is still time at home.
Lung cancer overlaps COPD in smokers and can add post-obstructive pneumonia, hemoptysis, SVC syndrome, and the solid-tumor functional drop. Do not attribute every new dyspnea in a COPD patient to “just COPD” when there is weight loss, hemoptysis, or a new focal finding.
Condition Typical hospice curve Oxygen / support trap
COPD Years of decline with recoverable exacerbations, then incomplete recovery Over-oxygenating CO2 retainers above about 88–92% saturation
IPF / fibrotic ILD Faster slide; exacerbations often terminal Assuming a bronchodilator burst will restore the COPD-like baseline
Pulmonary hypertension Right-heart failure, syncope, edema Stopping prostacyclin infusions without a crisis plan
Lung cancer plus COPD Solid-tumor drop plus obstruction or bleeding Treating only the COPD and missing the cancer emergency
Dyspnea crisis versus dying, NIV as palliation versus burden, opioids, secretions
A dyspnea crisis is sudden air hunger in a patient who is still perfusing: tripoding, accessory muscles, diaphoresis, wide-eyed panic, speaking in few-word sentences, strong pulse. Treat the crisis: positioning, fan, calm presence, oxygen to the appropriate target, a possible NIV trial, and an opioid. Morphine or hydromorphone are first-line dyspnea drugs in hospice and palliative care. They reduce air-hunger perception. Comfort doses are not the same as a planned respiratory arrest. Titration math is a later chapter; the Domain 1.C point is that opioids belong in the pulmonary toolbox, not only in the pain toolbox.
Active dying looks different: Cheyne–Stokes or agonal breathing, long apneas, mottling, fading pulses, less awareness. NIV in that phase is often a tight mask on a dying face—claustrophobia, skin breakdown, delayed last words. A time-limited NIV trial is honest palliation: if work of breathing falls and the patient can speak or rest, continue; if the mask only prolongs gasping, stop. COPD hypercapnic failure is the classic benefit setting. IPF and dying respiratory failure more often find NIV burdensome.
Secretion burden in advanced lung disease is pooled mucus the patient can no longer cough. Deep repeated suctioning can worsen distress. Repositioning, brief shallow suction if a plug is audible and the patient wants it, and later-chapter antisecretory drugs are the comfort path. Teach families that noisy upper-airway secretions in active dying are more a listener problem than a drowning; that distinction keeps you from treating dying as an airway emergency.